Advertisement
Canada markets close in 4 hours

  • S&P/TSX

    21,818.47
    -55.25 (-0.25%)
     

  • S&P 500

    5,017.40
    -54.23 (-1.07%)
     

  • DOW

    37,903.89
    -557.03 (-1.45%)
     

  • CAD/USD

    0.7303
    +0.0006 (+0.08%)
     

  • CRUDE OIL

    82.47
    -0.34 (-0.41%)
     

  • Bitcoin CAD

    87,682.90
    -810.50 (-0.92%)
     

  • CMC Crypto 200

    1,382.45
    -0.13 (-0.01%)
     

  • GOLD FUTURES

    2,342.60
    +4.20 (+0.18%)
     

  • RUSSELL 2000

    1,966.87
    -28.56 (-1.43%)
     

  • 10-Yr Bond

    4.7060
    +0.0540 (+1.16%)
     

  • NASDAQ

    15,477.14
    -235.60 (-1.50%)
     

  • VOLATILITY

    16.71
    +0.74 (+4.64%)
     

  • FTSE

    8,078.86
    +38.48 (+0.48%)
     

  • NIKKEI 225

    37,628.48
    -831.60 (-2.16%)
     

  • CAD/EUR

    0.6808
    -0.0011 (-0.16%)
     
BREAKING:

HONDA TO SET UP $15B EV PRODUCTION BASE IN CANADA

Automaker to get up to $5B in government assistance for EV battery, assembly plants

Is Trevena (TRVN) Outperforming Other Medical Stocks This Year?

Zacks Equity Research
·2 min read

The Medical group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. Is Trevena (TRVN) one of those stocks right now? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question.

Trevena is one of 889 companies in the Medical group. The Medical group currently sits at #1 within the Zacks Sector Rank. The Zacks Sector Rank considers 16 different sector groups. The average Zacks Rank of the individual stocks within the groups is measured, and the sectors are listed from best to worst.

The Zacks Rank is a proven system that emphasizes earnings estimates and estimate revisions, highlighting a variety of stocks that are displaying the right characteristics to beat the market over the next one to three months. TRVN is currently sporting a Zacks Rank of #2 (Buy).

Over the past 90 days, the Zacks Consensus Estimate for TRVN's full-year earnings has moved 26.47% higher. This is a sign of improving analyst sentiment and a positive earnings outlook trend.

ADVERTISEMENT

Based on the latest available data, TRVN has gained about 52.22% so far this year. At the same time, Medical stocks have lost an average of 1.90%. This means that Trevena is outperforming the sector as a whole this year.

Looking more specifically, TRVN belongs to the Medical - Biomedical and Genetics industry, a group that includes 382 individual stocks and currently sits at #18 in the Zacks Industry Rank. On average, this group has gained an average of 7.59% so far this year, meaning that TRVN is performing better in terms of year-to-date returns.

Going forward, investors interested in Medical stocks should continue to pay close attention to TRVN as it looks to continue its solid performance.


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
Trevena, Inc. (TRVN) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research